Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Ellmeier Elena |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Angiari, S; Carlucci, T; Budui, SL; Bach, SD; Dusi, S; Walter, J; Ellmeier, E; Schnabl, A; Tafrali, C; Demjaha, R; Khalil, M; Bordag, N; Laudanna, C; Rossi, B; Constantin, C.
Coenzyme A fueling with pantethine limits autoreactive T cell pathogenicity in experimental neuroinflammation
Harald von Boehmer Midwinter Conference 2024 “Advances in
Immunobiology”; January 20-24, 2024; Seefeld in Tirol, AUSTRIA. 2024.
[Oral Communication]
Angiari, S; Carlucci, T; Budui, SL; Bach, SD; Dusi, S; Walter, J; Ellmeier, E; Schnabl, A; Tafrali, C; Demjaha, R; Khalil, M; Bordag, N; Laudanna, C; Rossi, B; Constantin, G.
Coenzyme A fueling with pantethine limits autoreactive T cell pathogenicity in experimental neuroinflammation
Gordon Research Conference on Immunometabolism in Health and Disease; June 16-21, 2024; Bryant University, Smithfield, Rhode Island (USA). 2024.
[Poster]
Ellmeier, E; Carlucci, T; Budui, SL; Bach, SD; Dusi, S; Walter, J; Schnabl, A; Stracke, A; Tafrali, C; Demjaha, R; Khalil, M; Bordag, N; Angelini, G; Calore, A; Bani, A; Terrabuio, E; Zenaro, E; Laudanna, C; Rossi, B; Constantin, C; Angiari, S
Coenzyme A fueling with pantethine limits autoreactive T cell pathogenicity
in experimental neuroinflammation
BraYn Conference 2024; October 9-11, 2024; Verona (Italy). 2024.
[Oral Communication]
Ellmeier, E; Carlucci, T; Budui, SL; Bach, SD; Dusi, S; Walter, J; Schnabl, A; Tafrali, C; Demjaha, R; Khalil, M; Bordag, N; Angelini, G; Terrabuio, E; Zenaro, E; Laudanna, C; Rossi, B; Constantin, G; Angiari, S
Coenzyme A fueling with pantethine limits autoreactive T cell pathogenicity in experimental neuroinflammation
EUR J IMMUNOL. 2024; 54: 401-401.-7th European Conference of Immunology; SEP 01-04, 2024; Dublin, IRELAND.
[Oral Communication]
Web of Science
Ellmeier, E.; Walter, J.; Schwaminger, S.P.; Angiari, S.
Evaluating the role of succinate sensing via GPR91
in T cell mediated anti tumor immunity
nein. 2024; -Doc Day; Feb 2, 2024; Graz, AUSTRIA.
[Poster]
Schnabl, A; Ellmeier, E; Stracke, A; Seifried, K; Tafrali, C; Demjaha, R; Wurth, S; Khalil, M; Angiari, S
Targeting pyruvate kinase M2 to limit T cell pathogenicity in multiple sclerosis
EUR J IMMUNOL. 2024; 54: 74-74.-7th European Conference of Immunology; SEP 01-04, 2024; Dublin, IRELAND.
[Oral Communication]
Web of Science
Schnabl, A; Ellmeier, E; Stracke, A; Seifried, K; Tafrali, C; Demjaha, R; Wurth, S; Khalil, M; Angiari, S
Targeting pyruvate kinase M2 to limit T cell pathogenicity in multiple sclerosis.
Österreichische Gesellschaft für Neurologie (ÖGN) annual meeting 2024; March 13-15, 2024; Vienna, Austria. 2024.
[Poster]
Ellmeier, E; Schnabl, A; Seifried, K; Stracke, A; Tafrali, C; Demjaha, R; Khalil, M; Angiari, S
Targeting pyruvate kinase M2 to limit T cell pathogenicity in multiple sclerosis
ÖGAI Annual Meeting; September 14-16, 2023; Linz, AUSTRIA. 2023.
[Oral Communication]
Ellmeier, E; Stracke, A; Seifried, K; Tafrali, C; Khalil, M; Angiari, S
Targeting pyruvate kinase M2 to limit T cell pathogenicity in multiple sclerosis
6th BraYn Conference; September 27-29, 2023; Naples, ITALY. 2023.
[Oral Communication]